Delhi Journal of Ophthalmology

Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors

Jatinder Bali1, Ojasvini Bali2
1Narela Polyclinic and Health Complex, Delhi, India 
2Maulana Azad Medical College, Delhi, India

Editor-in-Chief, Delhi Journal of Ophthalmology, Dr R.P.Centre, AIIMS.

Corresponding Author:

Jatinder Bali (MS)
55-D, Third Floor, DDA FLATS, Kalidas Road, Gulabibagh, Delhi - 110007, India
Email id: 

Received: 16-SEP-2019 Accepted: 04-DEC-2019 Published Online: 21-JUN-2020

Glaucoma, the leading cause of irreversible blindness, blinds causes irreversible blindness in 4.0 million people worldwide. In India the estimated number of glaucoma patients is 12 million which is one fifth of the global morbidity of glaucoma.1 Elevation of intraocular pressure (IOP) is the only proven modifiable risk factor for most forms of glaucoma. Different etiological mechanisms have been proposed for increased IOP. Aqueous humor (AH) drainage from conventional or trabecular and uveoscleral pathway is a proven cause in most glaucoma patients and especially so in primary open angle glaucoma. IOP reduction slows vision loss and remains the mainstay of treatment for all types of glaucoma. Rho kinase is a serine/threonine protein kinase. It is a downstream effector of Rho GTPase, a Ras superfamily GTPase. it has a role in the conventional path of aqueous drainage. Rho Kinase (ROCK) inhibitors Ripasudil, K-115 and Netarsudil, AR-13503 have recently been approved for ophthalmological use in therapy of glaucoma as IOP-lowering agents. This is a brief overview of the Rho Kinase (ROCK) inhibitors.

Keywords :Glaucoma, netarsudil, rho kinase

Search PubMed for

Search Google Scholar for

Article Statistics